Toth Financial Advisory Corp Purchases 2,744 Shares of AbbVie Inc. $ABBV

Toth Financial Advisory Corp increased its position in AbbVie Inc. (NYSE:ABBV) by 6.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,982 shares of the company’s stock after acquiring an additional 2,744 shares during the quarter. AbbVie comprises about 1.2% of Toth Financial Advisory Corp’s investment portfolio, making the stock its 25th biggest position. Toth Financial Advisory Corp’s holdings in AbbVie were worth $11,110,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ABBV. Compton Wealth Advisory Group LLC lifted its position in shares of AbbVie by 1.7% during the 3rd quarter. Compton Wealth Advisory Group LLC now owns 11,769 shares of the company’s stock worth $2,725,000 after purchasing an additional 202 shares during the last quarter. ACT Advisors LLC. bought a new position in AbbVie in the 3rd quarter worth approximately $342,000. LVM Capital Management Ltd. MI lifted its holdings in shares of AbbVie by 1.4% during the third quarter. LVM Capital Management Ltd. MI now owns 169,664 shares of the company’s stock worth $39,284,000 after buying an additional 2,326 shares during the last quarter. Newman Dignan & Sheerar Inc. boosted its position in shares of AbbVie by 4.5% in the third quarter. Newman Dignan & Sheerar Inc. now owns 4,220 shares of the company’s stock valued at $977,000 after acquiring an additional 180 shares during the period. Finally, Central Bank & Trust Co. grew its stake in shares of AbbVie by 7.1% in the third quarter. Central Bank & Trust Co. now owns 2,236 shares of the company’s stock worth $518,000 after acquiring an additional 149 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $227.44 on Friday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $401.98 billion, a PE ratio of 172.30, a price-to-earnings-growth ratio of 1.29 and a beta of 0.36. The firm has a 50-day moving average price of $226.63 and a 200 day moving average price of $211.14.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the business earned $3.00 earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Citigroup cut their price objective on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. UBS Group lifted their target price on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Guggenheim boosted their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Finally, Scotiabank initiated coverage on AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.